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ABSTRACT
The recent elucidation of the genomic landscape of head and neck squamous cell 
carcinoma (HNSCC) has provided a unique opportunity to develop selective cancer 
treatment options. These efforts will require the establishment of relevant HNSCC 
models for preclinical testing. Here, we performed full exome and transcriptome 
sequencing of a large panel of HNSCC-derived cells from different anatomical 
locations and human papillomavirus (HPV) infection status. These cells exhibit typical 
mutations in TP53, FAT1, CDK2NA, CASP8, and NOTCH1, and copy number variations 
(CNVs) and mutations in PIK3CA, HRAS, and PTEN that reflect the widespread 
activation of the PI3K-mTOR pathway. SMAD4 alterations were observed that may 
explain the decreased tumor suppressive effect of TGF-β in HNSCC. Surprisingly, we 
identified HPV+ HNSCC cells harboring TP53 mutations, and documented aberrant 
TP53 expression in a subset of HPV+ HNSCC cases. This analysis also revealed that 
most HNSCC cells harbor multiple mutations and CNVs in epigenetic modifiers (e.g., 
EP300, CREBP, MLL1, MLL2, MLL3, KDM6A, and KDM6B) that may contribute to HNSCC 
initiation and progression. These genetically-defined experimental HNSCC cellular 
systems, together with the identification of novel actionable molecular targets, may 
now facilitate the pre-clinical evaluation of emerging therapeutic agents in tumors 
exhibiting each precise genomic alteration.
INTRODUCTION
HNSCC is the sixth most common cancer 
worldwide, with more than 500,000 new cases each year, 
of which only 40–50% will survive for 5 years. Over 
42,000 new cases of HNSCC are predicted to be diagnosed 
and 8,300 deaths to occur in 2014 from this disease in the 
United States alone [1]. Exposure to tobacco carcinogens 
combined with alcohol is a major risk factor in Western 
countries, while betel quid and areca nut chewing are risk 
factors commonly found in the south Asian region [2]. 
In the past few decades, sexually transmitted infection with 
high risk human papillomaviruses (HPV) has also emerged 
as a major risk factor, particularly affecting a younger 
population [3, 4]. Recent advances in HNSCC treatment 
have improved the quality of life and life expectancy of 
HNSCC patients if this disease is diagnosed at early stages 
[5]. However, the overall survival of HNSCC patients, the 
majority of which are diagnosed at advanced stages, has 
only improved marginally over the past 30 years. Currently, 
the most common HNSCC therapeutic modalities include 
the use of nonselective treatments (surgery, radiation and 
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chemotherapy) with very high systemic toxicities and 
associated morbidity and mortality. The development of 
more selective cancer treatment options for HNSCC will 
benefit from the complete understanding of the molecular 
mechanisms -and the underlying genetic alterations- in 
HNSCC carcinogenesis in order to identify actionable 
targets of therapeutic value.
In this regard, the development of novel therapeutic 
modalities invariably involves the initial evaluation in 
preclinical cancer models; hence the availability of relevant 
and well characterized biological systems is invaluable. 
For HNSCC, most preclinical studies have traditionally 
involved the use of widely available human HNSCC cell 
lines that form tumors in immunocompromised mice, 
some of which can also recapitulate the ability of HNSCC 
to invade loco-regional lymph nodes and even develop 
distant metastasis [6–8]. However, the lack of information 
regarding the primary molecular alterations in these 
cell lines has hampered the possibility of interpreting 
the emerging pre-clinical activity of recently developed 
therapeutic agents with the underlying mechanisms 
driving HNSCC progression. This is particularly relevant 
in the new era of precision medicine, in which the genetic 
alterations in each HNSCC lesions can now be assessed in 
a clinically relevant setting. Thus, building on prior multi 
institutional cancer sequencing efforts [9–12], we have 
now characterized the genetic alterations and expressed 
messages of a large collection of representative HNSCC 
lines, including normal immortalized oral keratinocytes as 
well as cell lines derived from HPV- and HPV+ oral tumor 
lesions. This HNSCC panel includes cell lines harboring 
the most frequent HNSCC alterations, which may now 
provide a valuable tool for the future development and 
evaluation of molecular-guided therapeutic options for 
HNSCC.
RESULTS
We selected a group of HNSCC cells (herein referred 
as oral and pharyngeal cancer (OPC)-22 panel) and 
subjected them to a thorough characterization involving 
short tandem repeat (STR) analysis, whole exome capture 
sequencing, and mRNA sequencing. Our primary goal 
was to develop a HNSCC cell line panel resembling 
the breadth and complexity of genetic alterations found 
in HNSCC at large. To preserve the genetic diversity 
found in HNSCC, we included HNSCC lines developed 
in cancer research centers covering distinct geographic 
locations, aimed at minimizing potential haplotype biases. 
We also included a non-transformed, spontaneously 
immortalized normal oral keratinocyte (NOKSI) cell 
line [13] which could provide additional insight into 
the molecular mechanisms involved in immortalization 
and premalignancy. The initial characterization of this 
panel involved STR profiling (Supplemental Table 1). 
We confirmed the correct identity of previously 
reported cell lines (CAL27, CAL33, Detroit 562, 
UM-SCC-47, SCC-25, SCC-9, UM-SCC-11B and UM-
SCC-17B) [6], while the information generated about 
previously unreported HNSCC cell lines should serve as 
a bona fide reference for future studies. Available clinical 
information on the OPC-22 cell lines compiled from 
different sources is provided in Supplemental Table 2.
The use of established cancer cell lines prevents 
somatic mutation calling by comparing the sequence 
information with respect to matched normal DNA, 
as the latter is usually unavailable. Thus, to identify 
putative somatic mutations in the HNSCC panel we used 
a variation of a production-level filtering strategy [14] 
involving the rejection of variants present in the dataset 
derived from the NIH/NHLBI ESP6500 project (variant 
frequency not equal to 0), and the rejection of variants 
present in more than 15% of the lines (3 cell lines) as 
putative uncharacterized SNPs, unless they were present 
in the COSMIC v64 database [16]. The latter was used 
to salvage true highly frequent mutations in cancer. For 
a comprehensive list of mutations see the Supplemental 
Data File 1.
Based on prior studies addressing the most common 
gene alterations in HNSCC [9, 10], we then compared their 
mutation frequency in the OPC-22 cell panel with respect 
to that found in the Cancer Genome Atlas consortium 
(TCGA) Head and Neck cancer provisional dataset, 
which currently comprises 306 HNSCC tumor samples 
(accessed through the cBioPortal, http://www.cbioportal.
org). Interestingly, the frequency of mutations in the OPC-
22 panel closely resembled that of the TCGA (Figure 1A). 
TP53 is the most frequently mutated gene both in HNSCC 
(69.9%) and the OPC-22 cell set (68.2%). Most of these 
alterations are present in the COSMIC database, while 
some additional novel TP53 mutations were detected in 
BICR22, WSU-HN12 and UM-SCC-2 cells, which are 
predicted to be deleterious (see Supplemental Table 3). On 
the other hand, TP53 gain of function (GOF) mutations 
H179L, V173L and R175H [17, 18] were detected in HN6, 
HN13 and CAL33 and Detroit 562 respectively.
In agreement with available information [19–21], 
activation of the PI3K/Akt/mTOR pathway is emerging 
as a leading oncogenic mechanism in HNSCC. The OPC-
22 panel nicely recapitulated the common occurrence 
of PIK3CA mutations (Figure 1A, upper panel) as well 
as PIK3CA gene amplification as depicted by copy 
number variation (CNV) analysis (Supplemental data 
file 2). In total, 9 out of 22 cell lines displayed either 
activating PIK3CA mutations or gene amplification, 
the latter noticeably overrepresented in HPV+ HNSCC 
lines (2 out of 4 HNSCC cell lines show amplification). 
Moreover, mutation of the PTEN phosphatase occurred in 
UPCI:SCC090 while homozygous deletion of PTEN was 
detected in UD-SCC-2, both derived from HPV+ HNSCCs. 
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Figure 1: The most frequent alterations in representative HNSCC-derived cells. (A) Top panel, graphical matrix representation 
of the individual mutations in 22 HNSCC cells and a normal spontaneously immortalized oral keratinocyte line (NOKSI, dark grey to denote 
the exclusion from the OPC-22 panel). Individual genes are represented in rows and cell lines in columns. In some cases more than one mutation 
per gene is present. For a comprehensive list see Supplemental Data File 1. The HPV status of each HNSCC-derived cell is represented in the 
bottom row. Second panel, PCR based promoter methylation analysis of the CDKN2A gene. Third panel, representative per-gene copy number 
variations as derived from comparison of each cell line to a computed pseudo-normal. Fourth panel, representative gene expression levels as 
determined by RNAseq data. Color code represents a log2 transformed fold expression normalized to the median of all samples. (B) Mutations 
in genes encoding histone modifying enzymes. Red square, mutation described in the COSMIC v64 database. Blue square, novel mutation. 
Red/Blue square, two or more mutations in a gene, one being novel and the other present on the COSMIC v64 database. Red square with 
inlay G, TP53 mutation present in the COSMIC v64 database defined as Gain-Of-Function. Green square, Gene copy loss, representing both 
hetero and homozygous deletions. Pink square, Gene copy gain, representing both copy gain and gene amplification. Black square, HPV status. 
Yellow square, CDKN2A promoter region methylation, no unmethylated product was detected. Yellow/Gray, CDKN2A promoter methylation 
analysis detected both methylated and unmethylated products. Light and dark grey squares, no change.
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HRAS activating mutations were detected at low frequency 
in HNSCC (3.3%), although this percentage was slightly 
higher (13.6%) in the OPC-22 set.
The protocadherin FAT1 is the second most mutated 
gene in HNSCC. In our panel this molecule was mutated 
in 5 of the cell lines (Figure 1A) and deleted in 2 (SCC- 25 
and SCC-9, see Supplemental Data File 2). FAT1 functions 
in HNSCC are not well understood, but it has been recently 
associated with the regulation of β-catenin complexes, 
therefore contributing to a migratory and invasive 
phenotype when its function is compromised [22, 23]. 
Another highly altered gene is the cell cycle inhibitor p16 
(CDKN2A), which presented either somatic mutations, 
extensive promoter methylation, as judged by PCR on 
bisulfite-treated genomic DNA (Figure 1A, second panel), 
or gene copy loss (Figure 1A, third panel). The NOTCH 
protein family has been recently identified as frequently 
mutated in HNSCC, and the functional implications 
of NOTCH alterations are now under investigation 
[9, 10, 24]. Loss of function alterations have been reported 
for all the family members, but they are more prominent in 
NOTCH1 (19%) and are similarly well represented in the 
OPC-22 panel (27.2%). The receptor associated caspase 
CASP8 is also frequently mutated in HNSCC [12], and 
its coding sequence is altered in 18% of the cell lines. In 
addition to its role in HNSCC development by preventing 
TNF-induced apoptosis [25], specific cancer-associated 
missense mutations have been recently shown to induce 
NF-κB activation [26], a well-established pro-oncogenic 
player in HNSCC [27].
Less explored mutations and genomic alterations 
were also identified in the OPC-22 panel. The antioxidant 
response master regulator NFE2L2 (NRF2) transcription 
factor [28] is frequently amplified and mutated in HNSCC 
(5.6%). Mutations in specific residues impair its interaction 
with the endogenous inhibitor and redox sensor KEAP1, 
which is also frequently mutated in HNSCC, ultimately 
leading to increased transcriptional activity and resistance 
to oxidative stress [29]. While no NFE2L2 mutations were 
identified in the OPC-22 panel, two HNSCC cell lines 
contained KEAP1 mutations of unknown function. The 
tyrosine kinase EPHA2 is mutated in a small number 
of HNSCCs (4%). Its role in HNSCC development and 
progression is not well understood [30], but its mutation 
profile, including a high fraction of nonsense and 
frameshift alterations suggest a tumor suppressive role. 
Interestingly, two cell lines in the OPC-22 panel and 
NOKSI contain mutations in the gene for this molecule, 
and include a frameshift (P212fs in UM-SCC-17B) and a 
nonsense mutation (W456X in NOKSI).
Of particular interest, SMAD4 was mutated in 3 of 
our cells lines, which is higher than expected based on 
the actual rate on the TCGA dataset. Although it is rarely 
mutated in HNSCC, the SMAD4 protein was found 
to be frequently lost (see below). Finally, we identified 
mutations in MAP4K3 (also called GLK), a kinase that has 
been recently identified as a component of the mTORC1 
complex and as an upstream regulator of the JNK pathway 
[31]. MAP4K3 is not frequently mutated in HNSCC 
(1.6%), but the mutation found in UM-SCC-17B (V322M) 
is identical to that identified in three cases of the Cancer 
Cell Line Encyclopedia (CCLE). Because its involvement 
in the regulation of mTOR by amino acids [31], MAP4K3 
has a potential role in HNSCC development.
We were unable to detect activating mutations 
of EGFR, but identified strong overexpression of its 
mRNA in HN6 and HN13 in (Figure 1A fourth panel). 
Likewise, overexpression of Cyclin D1 (CCND1) was 
very prominent among all the lines, except in the HPV+ 
group. Interestingly, MYC expression closely resembled 
that of CCDN1, perhaps indicating that the concomitant 
overexpression of CCDN1 and MYC contributes to 
HNSCC progression in the absence of HPV-specific 
oncogenic mechanism that may bypass this requirement.
Of note, multiple cell lines did not exhibit molecular 
alterations in readily identifiable oncogenic drivers, which 
is also apparent in many HNSCC cases analyzed in TCGA, 
and in agreement with other reports [9, 10]. In search 
for candidate transforming events, we noticed that two 
histone methyltransferases, NSD1 and KMT2D (MLL2) 
belonging to the family of epigenetic regulators rank 
amongst the most frequently mutated genes in HNSCC. 
In fact, when we studied the presence of mutations in 
molecules involved in epigenetic gene expression control 
(Figure 1B), we found a surprisingly high incidence of 
alterations throughout the HNSCC panel. Only 4 out of 
the 22 cells lines showed no alterations in epigenetic 
modifying enzymes, while the rest contained at least 
one if not multiple overlapping alterations in key histone 
modifiers. In this regard it is interesting to note that most 
alterations are predicted to be deleterious mutations, and 
therefore interfering with epigenetic regulation. Despite 
the potential functional redundancy of the epigenetic 
regulating machinery, we noticed that very specific 
functions seem to be highly represented. For example, the 
EP300 and CREBBP histone acetyltransferases, which 
play a crucial role in the activation of gene expression, 
are frequently altered (12.9%) in a non-overlapping 
fashion in all cases analyzed in TCGA. These alterations 
seem to be much more prominent in HNSCC lines, 
where we detected alteration in either EP300 or CREBBP 
in almost 50% of the cases. While the reason for this 
increased representation of EP300/CREBBP mutations 
in HNSCC cells lines is unclear, it is possible that these 
alterations diminish differentiation and thereby enables the 
establishment of HNSCC cell cultures.
Another interesting example is the frequent 
alteration of KDM6A (UTX) and KDM6B (JMJD3). These 
two molecules are the only enzymes displaying H3K27 
di- and tri-demethylase activity and are strictly required 
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for the reactivation of genes that have been epigenetically 
silenced. These molecules are mutated in 2.6 and 1.7% 
of HNSCC cases deposited in TCGA, respectively, in a 
mutually exclusive fashion. When including alteration 
due to copy number variation (Supplemental Table 4), 
we observed that KDM6A is homozygously deleted in 
an additional 5% of the tumors in TCGA. However, due 
to the location of KDM6A in the X chromosome this 
gene product is highly sensitive to hemizygotic loss, an 
event that is detected in 29.5% of HNSCC cases in 
TCGA. Considering mutations, hemi- and homozygotic 
loss of KDM6A elevates the number of altered HNSCC 
cases to 36.7%, highlighting the prominent alteration 
of this molecule in HNSCC. Moreover, KDM6B is also 
frequently hemizygously deleted (24.8%) and in over 
10% of the cases both enzymes are hemizygously deleted, 
and therefore total H3K27 demethylase gene dosage is 
effectively halved.
We next sought to confirm the predictive value 
of exome and mRNA sequencing by analyzing relevant 
alterations in our panel. mRNA sequencing revealed 
high EGFR expression levels on WSU-HN6 and WSU-
HN13 cell lines, which was readily observed as increased 
protein levels by Western blot in these two particular 
cells lines (Figure 2A). Moreover, copy number variation 
analysis derived from exome sequencing data detected 
the homozygous deletion of the PTEN phosphatase in 
UD-SCC-2 cells in agreement with the complete absence 
of PTEN protein expression. These two events can 
potentially lead to the activation of the mTOR kinase 
which itself is a widespread event in HNSCC tissues 
and cell lines [20, 21, 32]. As shown in Figure 2A, 
phosphorylation of the mTOR targets AKTS473 and the pS6 
is prominent in all HNSCC cell lines.
Persistent HPV infection with high risk HPV types, 
primarily HPV16, is emerging as a leading risk factor 
for the development of HNSCC [3, 33]. Four of the cell 
lines in the OPC-22 panel have been previously reported 
to be HPV+ [6, 34, 35], namely 93VU147T, UM-SCC-47, 
UPCI:SCC090 and UD-SCC-2. Expression of the p16 
product of the CDKN2A gene, an inhibitor of the G1/S 
regulator CyclinD-cyclin dependent kinase (CDK)4/
CDK6, has traditionally been used as a surrogate marker 
of HPV infection [13, 36]. Under normal conditions, p16 
expression is epigenetically silenced [37]. Due to the 
dysregulation of the RB tumor suppressor by binding to the 
HPV-encoded E7 oncoprotein, RB no longer needs to be 
inactivated by CDK4/6-mediated phosphorylation, and this 
leads to cell cycle progression and cell proliferation despite 
the massive accumulation of cell cycle inhibitors such as 
p16 [38]. Interestingly, we observed elevated expression 
of p16INK4A by Western blot in all the HPV+ cells (Figure 
2B). Moreover, PCR amplification and sequencing of 
genomic DNA revealed the presence of E7-like product in 
all the HPV+ HNSCC lines (Figure 2C). Sanger sequencing 
of the resulting amplicons confirmed the presence of 
HPV16 infection in every case (Figure 2C, lower panel). 
This is in agreement with the notion that HPV16 is 
the most common high-risk HPV type in HNSCC [3].
Due to the molecular function of the HPV E6 
oncoprotein TP53 alterations are expected to be absent in 
HPV positive HNSCCs as depicted by prior studies [9, 10]. 
However, one of the HPV positive lines, 93VU147T, 
exhibited a TP53 mutation (L257R) predicted to be 
deleterious. Therefore we wanted to address if the presence 
of TP53 alterations in HPV-related HNSCCs is a more 
common event in HNSCC than previously recognized. We 
studied the co-expression of TP53 and p16INK4A proteins in 
a cohort of 126 cases of HNSCC. Detection of TP53 by 
immunohistochemistry is frequently used as an indication 
of mutated or inactive TP53 [39]. As shown in Figure 
2D, the majority of the HNSCC samples show only TP53 
staining (52.38%), and a smaller number showed only 
p16 staining (16.66%). However, 3.17% of the samples 
showed a co-staining of p16 and TP53. In this regard, we 
observed two distinct patterns of TP53 staining in p16 
positive tumors. About half of the HPV+ samples displayed 
extensive TP53 staining while the other displayed small 
clusters of TP53 positive tumor cells, probably representing 
small clonal populations within the tumor.
As described above, another frequent alteration 
detected in the HNSCC cell panel was the presence of 
inactivating mutations of SMAD4. This co-SMAD is 
strictly required for proper receptor-SMAD (R-SMAD) 
signaling downstream of TGF-β receptor family, including 
TGFBR1/2 as well as the bone morphogenetic protein 
(BMP) and activin receptors [40]. Two cell lines in our 
panel, CAL27 and CAL33, harbor truncating mutations 
of SMAD4, while UM-SCC-2 displayed a H132Y 
mutation predicted to be deleterious (PROVEAN score 
-5.490). While the frequency of SMAD4 mutations 
reported in the TCGA dataset is low (2%), this gene is 
very frequently hetero and homozygously deleted (48.7 
and 4.6%, respectively). We validated our sequencing 
observations by studying the expression of SMAD4 in 
CAL33 and UM-SCC-2 cells, exhibiting a truncated and 
mutant SMAD4, respectively, using an antibody that 
recognizes the c-terminus of SMAD4. We were able to 
detect cytoplasmic and perinuclear SMAD4 staining 
in UM-SCC-2 xenografts, but failed to detect SMAD4 
expression in CAL33 tumors while strongly reacting with 
the mouse stroma (Figure 3A). These findings prompted 
us to screen a HNSCC tissue array for SMAD4 expression 
by immunohistochemistry in order to better assess the true 
frequency of SMAD4 alterations in HNSCC at the protein 
level. We identified the absence of detectable SMAD4 
expression in ~18% of the samples (n=44, Figure 3B).
Because TGF-β signaling elicits both pro-
proliferative and tumor-suppressive responses depending 
on the biological context [40], we addressed the specific 
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Figure 2: Exome sequencing data validation. (A) Biochemical characterization of alterations in PI3K-mTOR predicted by whole 
exome and RNAseq data for representative cell lines. Exponentially growing cultures were serum starved overnight and then lysed. A 
representative Western blot is shown for each indicated protein and phospho-protein. (B) Analysis of CDKN2A (p16) levels in HPV+ 
cell lines. (C) Upper panel, status of HPV infection by LCR-E7 PCR. HPV type identities were determined by Sanger sequencing of the 
LCR-E7 PCR amplicons. (D) A representative example of a cohort of 126 HNSCC tumors for which HPV status and TP53 mutation was 
evaluated as judged by immunohistochemical staining. A proportion of HPV+ (p16+) cases displays TP53 immunoreactivity, indicating the 
accumulation of TP53 mutant forms. TP53 staining in HPV+ samples varied in proportion and intensity. A quantification of the results of 
this study is presented in the lower panel.
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Figure 3: Aberrant TGF-β signaling in HNSCC and the OPC-22 panel. (A) Sequencing data identified the presence of 
mutations in CAL33 and UM-SCC-2 as indicated. A representative SMAD4 staining on tumor xenografts with an antibody raised against 
the C-terminus of SMAD4 detected expression (brown) in UM-SCC-2 tumors and mouse stroma, while CAL33 tumors were negative. 
Tumor areas are delimited by a dashed line. Dotted area insets are shown at higher magnification in the corresponding lower panels. 
(B) Analysis of a cohort of 44 HNSCC cases stained for SMAD4. A representative negative (left) and positive (right) case is shown. Whole 
cohort quantification is shown in the lower panel. (C) Analysis of the TGF-β signaling in select HNSCC-derived lines. Cells were cultured 
under exponential growing conditions and then serum starved overnight. Cells were stimulated with vehicle (-) or 100 ng/ml TGF-β (+) for 
45 minutes. Cells lysates were analyzed by Western blot for the proteins and phospho-proteins indicated in the figure. (D) Cells cultured as 
in C, were stimulated for 6h with vehicle (black bars) or 100 ng/ml TGF-β (white bars) and then RNA was extracted. SMAD7 expression 
was determined by qPCR. n=4, *, p≤0.05 for TGF-β different from Control. (E) A doxycycline inducible Flag-SMAD4 WT-IRES-GFP 
lentivirus was engineered and used to infect HNSCC as indicated. The percentage of SMAD4 WT expressing cells was determined to be 
over 70% in each case by GFP analysis. Cells cultured in the presence of 1 μg/ml doxycycline for 18h were lysed and analyzed by Western 
blot. (F) Cells in exponentially growing conditions were serum starved 12h in the presence of 1 μg/ml doxycycline and then stimulated for 
6h with vehicle (black bars) or 100 ng/ml TGF-β (white bars). RNA was then extracted and SMAD7 expression levels determined by qPCR. 
n=4, *, p≤0.05, **, p≤0.01. (G) Cell proliferation assay by [3H]-thymidine incorporation. Exponentially growing cultures in the presence 
or absence of doxyclycline as indicated for 24h. Cells were then serum starved and treated with TGF-β while maintaining doxycycline 
treatment. [3H]-Thymidine (1µCi) was added to the cultures 4 h before the end of the treatment (total treatment time 24h). n=4, *, p≤0.05, 
***, p≤0.001
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impact of TGF-β dysregulation in HNSCC in cell lines 
harboring SMAD4 alterations (CAL27, CAL33 and 
UM-SCC-2), using non-tumorigenic, spontaneously 
immortalized normal oral keratinocytes (NOKSI) and 
a SMAD4 wild type containing HNSCC line (BHY) as 
controls. As shown in Figure 3C, treatment with TGF-β 
induced the robust phosphorylation of the downstream 
R-SMAD SMAD2 in all cells except CAL27. Concomitant 
SMAD3 phosphorylation was also absent in CAL27 and 
UM-SCC-2 cells. Further analysis revealed that the failure 
to properly phosphorylate R-SMADs in CAL27 is likely 
due to the presence of a deleterious mutation in TGFBR1 
(N45S, PROVEAN score -3.275). SMAD4 levels were 
very low in both CAL27 and CAL33, as expected. Despite 
proper activation of at least one R-SMAD in CAL33 and 
UM-SCC-2, TGF-β failed to induced gene expression 
of SMAD7, a prototypical transcriptional target of 
TGF-β signaling and negative regulator of the pathway 
(Figure 3D).
In order to address the biological role of SMAD4 
inactivation in HNSCC we sought to rescue SMAD4 
function by infection with an inducible lentivirus 
encoding a Flag-tagged wild type version of SMAD4. 
As show in Figure 3E, we successfully generated 
doxycycline-inducible SMAD4 expressing HNSCC cell 
lines, as reflected by Flag immunodetection. We then 
challenged the Flag-SMAD4 expressing cell lines with 
TGF-β (Figure 3F), and observed a substantial recovery 
of SMAD7 expression in CAL33 cells, while CAL27 
and UM-SCC-2 remained insensitive. We concluded that 
TGFBR1 alterations in CAL27 impairs TGF-β signaling, 
while in the absence of other detectable abnormalities 
in the pathway, the SMAD4 H132Y mutation present in 
UM-SCC-2 likely behaves as a dominant negative protein, 
effectively preventing SMAD2/3-mediated transcription in 
this HNSCC line.
Finally, we asked whether impaired TGF-β provided 
any proliferative advantage in these cell lines. We 
conducted a cell proliferation assay in these engineered 
cell lines (Figure 3G) and observed that TGF-β treatment 
decreases the proliferation of both NOKSI and BHY 
cells. This antiproliferative response was absent in cells 
where TGF-signaling was defective (CAL27, CAL33 and 
UM-SCC-2). Interestingly, when SMAD4 expression was 
restored via induction with doxycycline, CAL33 showed a 
significant reduction in proliferation in response to TGF-β, 
while CAL27 and UM-SCC-2 remained refractory, 
mirroring the induction of SMAD7 expression changes 
observed in Figure 3F. We therefore concluded that the 
role of TGF-β signaling in HNSCC is antiproliferative, 
in agreement with previous reports [41], and that this 
response is dependent on proper R-SMAD and co-SMAD 
signaling leading to productive TGF-β gene expression 
regulation.
We next performed an analysis of the  OPC-22 
transcriptome in order to identify global changes in 
gene expression in HNSCC cells. Initial quality control 
identified the expression profile of UM-SCC-17B 
as an outlier, likely due to technical issues, and was 
removed from subsequent analyses. To identify the most 
representative differentially expressed transcripts between 
immortalized oral keratinocyte lines and the HNSCC cells, 
we employed the edgeR test as statistically supervised 
method (Figure 4A). This analysis revealed 230 genes 
differentially expressed (FC>2; FDR<0.01) of which 90 
were upregulated and 140 were downregulated transcripts 
in HNSCC cells (Supplemental Data File 3). Functional 
analysis of the deregulated gene list identified statistically 
significant enrichment of biofunctions associated to 
several metabolic processes, protein folding and cell 
signaling related to FGFR1, PI3K/AKT and MAPK cascade 
pathways (Figure 4B). To identify affected transcriptional 
regulatory networks, we performed a transcription factor 
enrichment analysis from the deregulated gene list. This 
allowed us to identify a set of transcription factors whose 
activity is potentially upregulated in HNSCC cells, which 
included HIF1α, NFκB1 and JUN, and the CDKN2A 
suppressor ZBTB7A [42] (see Supplemental Data File 4).
Because HPV-associated HNSCCs represent a 
distinct clinical entity, we took advantage of the sequence 
information of the HNSCC HPV+ cell transcriptome 
to help define its unique transforming mechanisms. By 
performing a supervised class comparison between the 
HPV+ and HPV- cells lines in the panel, we identified 
109 differentially regulated genes (>2 Fold change, 
p<0.05, Supplemental Data File 5). Analysis of 68 
upregulated genes helped identify a significant enrichment 
(Supplemental Data File 6) in several upstream regulators 
(transcription factors) including MZF1, MYC/MAX, 
YAP/TEAD2 and E2F1, while the downregulated 
genes (n=41) appeared to be enriched on transcriptional 
targets of the NF-κB/RELA, NR5A2, STAT1, SMAD4 
and SNAIL transcription factors and MIR133B and 
MIR138 microRNAs (Figure 4C). A scheme representing 
potential biological consequences based on the predicted 
transcriptional events responsible for the gene expression 
profile of HPV+ cell lines is presented in Figure 4D, 
thus suggesting multiple unique molecular mechanisms 
that might underlie HPV-associated head and neck 
malignancies.
DISCUSSION
The rapid progress of targeted therapies and our 
increased understanding of the molecular basis of HNSCC 
may soon enable personalized medicine approaches based 
on the genetic and epigenetic alterations of each tumor 
lesion. However, the development of new precision 
molecular treatment options requires the availability of 
suitable preclinical models. Here, we have characterized 
a representative panel of HNSCC cells lines reflecting the 
most frequent genetic alterations observed in HNSCC. 
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Figure 4: Gene expression analysis of the OPC-22 panel. (A) Supervised clustering analysis of the OPC-22 HNSCC lines on 
differentially expressed genes (FDR<0.01, Fold change ≥2) when comparing HNSSC lines to normal. Two additional normal cells lines 
(NOK6 and NOK16) represent two additional independent isolates from the same donor and were included in this analysis for statistical 
purposes. UM-SCC-17B was removed from the analysis due to outlier expression profile. (B) Functional enrichment analysis on biological 
processes on differentially expressed genes using the ClueGO tool. (C) Genes differentially expressed between HPV+ and HPV- groups 
(Moderated T-test, p<0.05, fold change >±2) were analyzed by the Enrichr tool against the TRANSFAC and JASPAR position weight 
matrices (PWMs) for predicted transcription binding sites in their respective promoter regions. The combined score is a positive value 
computed by taking the log of the p-value from the Fisher’s exact test and multiplying that by the z-score of the deviation from the expected 
rank. Enrichment scores derived from the downregulated gene list were given negative value for representation purposes. (D) Schematic 
representation of a hypothetical HPV E6/E7 interaction network leading to differential gene expression in the OPC-22 HPV+ cohort.
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This biologically relevant experimental system will 
be important to study the impact of specific treatment 
options based on each genomic alteration. In addition, 
many of these HNSCC cells have been used extensively; 
hence there is wealth of biochemical and biological data 
already available worldwide that can now be re-analyzed 
retrospectively in light of the molecular alterations 
underlying each HNSCC cell model.
In this regard, prior efforts have provided an initial 
genomic characterization of several HNSSC cell lines, 
some of which are also included in our study [43–45]. 
In the current study, all cells lines have been sequenced 
and analyzed using a common platform, thus minimizing 
methodological biases. Two other critical differences are 
that our current study extends the geographical diversity of 
HNSCC cells as they were collected from different sources 
around the world, and that the present HNSCC cell panel 
included a cohort of HPV+ cell lines. Indeed, given the 
increasing number of HPV-related HNSCC cases, with a 
clear tendency to increase in the future [3], the inclusion of 
4 different HPV+ HNSCC cell lines may now help reflect 
the genomic and gene expression characteristics of HPV+-
associated HNSCC. Therefore the OPC-22 panel may 
provide a relevant biological and molecular toolbox for the 
study of HNSCCs exhibiting distinct genetic alterations 
and HPV status.
A number of emerging themes can be derived from 
the systematic analysis of the OPC-22 panel. Firstly, it 
reinforces multiple observations that deregulation of the 
PI3K-mTOR pathway may represent a key oncogenic 
driving mechanism in HNSCC [19]. Mutations and 
amplification of PIK3CA are frequent in HNSCC, whereas 
PTEN mutations or deletions are not [9–12, 19]. It is 
therefore intriguing that alterations in PIK3CA and PTEN 
accumulate within the HPV+ cells lines, as reflected by 
the fact that we found PTEN mutated (UPCI:SCC090) or 
homozygously deleted (UD-SCC-2), and that PIK3CA 
is consistently amplified (93VU147T, UM-SCC-47, 
UPCI:SCC-90, UD-SCC-2). These findings suggest that 
robust PI3K pathway activation in a TP53 and RB inactive 
background conferred by the function of the HPV E6/E7 
oncoproteins might be sufficient to induce HNSCC tumor 
progression. This might have direct implications in the 
management of HNSCC, as PIK3CA and RAS activating 
mutations in HNSCC cells both confer resistance to 
cetuximab, an EGFR-targeted antibody commonly used 
as a first line treatment in HNSCC patients [46].
Another interesting observation was a broad 
dysregulation of the TGF-β signaling system in HNSCC. 
Previous reports indicated the infrequent alteration of 
SMAD4 in HNSCC [47], and indeed, the mutation 
frequency of SMAD4 as defined by the TCGA dataset is 
low (2%). However, we found that additional SMAD4 
alterations such as homo- and heterozygous deletions are 
much more frequent (5% and 49%, respectively). Hence, 
loss of expression due to gene deletion is likely the most 
relevant mechanism leading to SMAD4 inactivation in 
HNSCC, while mutations leading to early termination 
codons as well as other inactivating and dominant 
negative mutations may compromise SMAD4 function in 
a large fraction of HNSCC cases. Based on our analysis 
of HNSCC cell lines and the information available at the 
TCGA, SMAD4 alterations disrupting TGF-β signaling 
are likely close to 20%. Indeed, in our analysis of HNSCC 
tissue arrays, SMAD4 expression was undetectable in 
18% percent of the cases. We can also speculate that 
because of the crucial role of SMAD4 in TGF-β induced 
transcriptional regulation, even a modest decrease in 
SMAD4 levels could explain the compromised tumor-
suppressive role of TGF-β in HNSCC [41].
The high frequency of TP53 and CDKN2A 
mutations highlights the key roles of these tumor 
suppressor genes in HNSCC development. This likely 
reflects the pre-requirement of their alteration to promote 
tumor progression and therefore representing one of the 
earliest events during malignant transformation in HNSCC 
[48]. The infection with sexually transmitted high risk 
mucosal HPV provides a molecular mechanism to bypass 
the need of such alterations, therefore enabling HNSCC 
development in patients in the absence of carcinogen-
induced TP53 mutations that are characteristic of classical 
risk factors, such as tobacco and alcohol and betel quid or 
areca nut chewing [48]. In this regard, it seems paradoxical 
that most HPV-positive tumors in previous high scale 
genomic studies [9, 10] were devoid of TP53 mutations, 
suggesting that HPV infection precluded the accumulation 
of TP53 mutations, or that patients with HPV-associated 
HNSCC were not exposed to other classical risk factors. 
In contrast to these possibilities, our analysis in HNSCC 
cell lines, HNSCC lesions, and recent studies [49] suggest 
that alteration in TP53 in HPV+ tumors are more frequent 
than previously expected.
One possible explanation of this discrepancy is that 
while TP53 mutations are widespread amongst the tumor 
mass due to its contribution to initiation and subsequent 
progression of HNSCC cases associated with classical 
risk factors, TP53 mutant cell clones in HPV-associated 
HNSCC cases may be more limited, in some cases 
amounting to just 1–10% of the tumor mass. Therefore 
early sequencing efforts might have been hampered by 
technological limitations in sequencing depth and mutation 
calling thresholds could have overlooked this fact. These 
findings may have direct clinical implications, as HPV+ 
HNSCCs respond better to chemoradiation, leading 
to a current trend towards dose de-escalation in HPV+ 
HNSCC cases [50]. This therapeutic option may reduce 
the overall tumor mass with lower undesirable side effects, 
but patients harboring TP53 mutations, a typical event in 
tobacco users [48] concomitant with HPV infection may 
be at higher risk of tumor relapse after treatment. If this 
were the case, the prediction that tumor recurrence in 
HPV+ HNSCC cases would involve a higher proportion 
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of tumor cells exhibiting TP53 mutations could be readily 
testable in the future, which could directly impact the 
choice of treatment modality based on the analysis of HPV 
infection and TP53 status.
Another emerging observation is that the OPC-22 
panel mirrored the absence of prototypical oncogenic 
drivers in a fraction of HNSCC cases [9, 10, 51], such 
as in CAL27, WSU-HN6 and WSU-HN8. This suggests 
that long term culture conditions do not result in the 
appearance of typical oncogenic drivers [52]. This 
also raises the possibility of the existence of additional 
oncogenic mechanisms yet to be characterized in HNSCC. 
In this regard, epigenetic dysregulation is a key event 
during cancer development in many tumor types, and 
epigenetic modifiers consistently rank among the most 
frequently mutated genes in human cancer [53, 54]. Thus, 
we can hypothesize that in the absence of other evident 
oncogenic mechanisms, epigenetic alterations might 
provide a plausible alternative by abnormally modifying 
gene expression profiles, resulting in cancer growth.
Specifically, we found a widespread alterations 
in multiple orthologs of the Drosophila melanogaster 
Trithorax group (trxG), which are best known for their 
fundamental role in leukemias [53, 55]. These molecules 
form part of a multiprotein complex regulating epigenetic 
events. Among them, MLL1, MLL2 and MLL3 are 
frequently mutated in HNSCC, together with the H3K27 
demethylases KDM6A and KDM6B (UTX and JMJD3, 
respectively) [55]. Their mutation profile suggests a 
profound loss of function phenotype. During stem cell 
fate specification, these molecules are essential for the 
activation of expression of epigenetically silenced genes 
[56]. This is also the case for multiple tumor suppressors, 
which are epigenetically silenced until an oncogenic 
stimulus provokes their activation, such in the case of 
the p16 protein product from the CDKN2A locus [57]. 
Aligned with this possibility, all MLL3 mutated cell lines 
display CDKN2A promoter methylation. As cell self-
renewal (stemness) maintenance is a hallmark of cancer 
[58], we can hypothesize that disrupting the function of 
the trxG complex may represent a driving oncogenic event 
in HNSCC, as it will interfere with the deployment of 
tumor suppressive mechanisms, including cell cycle arrest 
and the initiation of epithelial terminal differentiation 
programs. These possibilities and the recent development 
of multiple drugs targeting the epigenetic regulating 
machinery [59] may provide a rationale for the further 
exploration of epigenetic modifying agents as alternative 
targeted therapies in HNSCC, with emphasis on HNSCC 
cases that do not harbor obvious alterations in driver 
oncogenic pathways.
Finally, we observed that, despite the diversity 
of genotypic alterations present in the OPC-22 panel, 
their gene expression patterns converge into the 
recurrent dysregulation of a number of gene expression 
modules that are widely altered in HNSCC, including 
the widespread dysregulation of multitude of metabolic 
processes, likely reflecting the metabolic reprogramming 
recently identified as one of the hallmarks of cancer 
[58]. In this regard, however, the study of differentially 
expressed genes in HPV+ cell lines may now provide 
interesting clues on the molecular mechanisms involved 
in HPV-induced malignancies. Together with well-known 
oncogenic events induced by the E6/E7 oncoproteins, such 
as the inactivation of TP53 and the persistent stimulation 
of E2F transcription factors due to RB1 inhibition [38], 
the specific HPV+ gene expression profiles suggest that 
other less studied mechanisms might also contribute to 
HPV-driven HNSCC development. In particular, our 
transcriptome analysis suggests that HPV oncogenes could 
regulate both transcription factors MYC and TEAD2, 
the latter requiring the stimulation of the transcriptional 
co-activator YAP, both of which can initiate oncogenic 
signaling and prevention of cell differentiation [60, 61]. 
HPV-oncogenes my also promote the activation of the 
MZF1 transcription factor, which harbors tumorigenic 
potential [62]. On the other hand, we also observed 
that HPV+ HNSCC cells exhibit lower activity of 
NF-κB/RELA, a pro-survival and –inflammatory 
transcription factor, which may explain the decreased 
activation of the innate immune system and increased 
sensitivity to pro-apoptotic radio- and chemotherapeutic 
agents in HPV+ tumors [63]. Recently, focal deletions on 
the TRAF3 gene have been identified in HPV+ HNSCC 
cases [64], which can potentially impact both NF-κB and 
interferon signaling [65]. We identified TRAF3 copy loss 
in the HPV+ UPCI:SCC090 cell line, which could partially 
contribute to the differential gene expression profile 
displayed by these cells. In addition, our analysis suggests 
that other additional mechanisms could contribute to 
HPV-associated malignancies. These include a decreased 
host antiviral response through impairment of STAT1 
function by E6 during the Interferon-α response [66], 
decreased TGF-β-dependent gene expression leading 
to an impairment of epithelial differentiation, and the 
regulation of miRNA138 and miRNA133B, which have 
been characterized for their tumor suppressive activity in 
HNSCC [67, 68], thus opening new avenues for future 
research in HPV-driven cancers.
In summary, HNSCC display a handful of 
widespread genomic alterations, which can now be 
evaluated as potential molecular targets for personalized 
medicine. TP53 alterations are among the most frequent 
events in HNSCC, therefore TP53 reactivating molecules 
could potentially have a wide impact in HNSCC 
development and progression. Alterations in the CDKN2A/
CDKN2B locus are also highly frequent. Overactive 
CDK4/CDK6 after CDKN2A loss may be sensitive 
to newly developed CDK inhibitors [69]. However, 
as a significant proportion of CDKN2A/CDKN2B 
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alterations are due to gene inactivation by promoter and 
gene methylation, their gene reactivation by the use of 
small molecules targeting the epigenetic machinery, 
including histone and DNA methylases and acetylases, 
could represent an attractive HNSCC management 
strategy [70]. As described above, this emerging class 
of mechanism-based therapies could be particularly 
attractive for HNSCC lesions harboring mutations in 
epigenetic modifying enzymes but lacking alterations in 
typical driver oncogenic pathways. In this regard, multiple 
genomic alterations converging in the activation of the 
PI3K/AKT/mTOR pathway may explain the overeactivity 
of this signaling route in most HNSCC [19–21], which 
provided a rationale for multiple currently open clinical 
trials targeting PI3K, mTOR, as single agents and as part 
of combination therapies.
The recent elucidation of the genomic landscape of 
HNSCC has provided a unique opportunity to understand 
the molecular basis of HNSCC. In this regard, our current 
analysis of HNSCC-derived cells have identified multiple 
alterations underlying the decreased tumor suppressive 
effect of TGF-β in HNSCC, underscores the presence 
of TP53 mutations in a subset of HPV+ HNSCC cases, 
and revealed wide spread mutations and copy number 
variations in epigenetic modifiers, particularly of the 
Trithorax gene group. The latter may contribute to 
HNSCC initiation and progression in a large fraction of 
HNSCC cases lacking typical oncogenic drivers. Overall, 
we can conclude that the development of experimental 
cellular systems reflecting the most frequent oncogenic 
events in HNSCC together with the identification of novel 
actionable molecular targets may now facilitate the pre-
clinical evaluation of emerging therapeutic modalities for 
their effectiveness in tumors exhibiting each particular 
genomic alteration underlying HNSCC progression.
METHODS
Cell lines and culture conditions
All cell lines were culture under the same conditions 
except the ones listed below. HNSCC lines were cultured 
on DMEM (D-6429, Sigma-Aldrich, St. Louis, MO), 10% 
fetal bovine serum, 5% CO2, at 37°C. UPCI:SCC090, 
UM-SCC-47 were grown on 50/50 v/v DMEM/F12 
media supplemented with 10% FBS. The spontaneously 
immortalized NOKSI, NOK6 and NOK16 lines were 
grown on Defined Keratinocyte-SFM (Invitrogen, 
Carlsbad, CA).
DNAs
To generate the lentiviral vector pLTiTSA-Smad4-
Flag plasmid, the Smad4-Flag cDNA was excised 
from a pRK5-SMAD4-Flag plasmid [71] using EcoRI/
SalI digestion, gel purified and ligated into a pENTR 
SfiI Shuttle previously linearized with EcoRI/XhoI. 
Subsequently, the SMAD4-Flag insert was transferred 
into a Gateway modified pLTiTSA GW (TREtight-GW-
IRES-tomato, SV40-rtTA) [72] via Gateway reaction 
(Invitrogen).
Antibodies
Antibodies anti EGFR, TGFBR1 and p16 (JC8) 
were purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA). Mouse monoclonal Anti-Flag (M2) antibody 
was purchased from Sigma. Antibodies against PTEN, 
phospho-AKTS473(XP), AKT, phospho-S6, S6, SMAD4, 
SMAD2, phospho-SMAD2, SMAD3, phospho-SMAD3 
and Tubulin-HRP were purchased from Cell Signaling 
Technology (Beverly, MA). For immunohistochemistry 
studies, monoclonal mouse anti-human TP53 antibody 
was purchased from Dako (Carpinteria, CA) and a CINtec 
p16 staining kit was purchased from Roche Diagnostics 
(Madison, WI).
Immunohistochemistry
H&E stained paraffin sections were used for 
histopathological evaluation. For immunohistochemistry, 
5 μm unstained paraffin sections were deparaffinized 
in 3 changes of SafeClear II (ThermoFisher Scientific, 
PA, USA), 5 min each, and the hydrated with graded 
alcohols (100°, 95°, 70°), 2 changes each, 5 min each. 
The endogenous peroxidase was blocked by incubating 
for 30 min in 3% H2O2 in 70° ethanol. Antigens were 
retrieved with 10 mM citric acid (2.1 g/L) in a microwave 
oven, 2 min at 100% power, followed by 18 min at 
20%. The slides were allowed to cool for 15 min and 
washed extensively with distilled water, followed by 
3 changes of PBS, 5 min each. After blocking with 
2.5% BSA in PBS at room temperature, for 30 min, 
the slides were incubated overnight at 4°C with the 
appropriate primary antibodies diluted in 2.5% BSA in 
PBS. The slides were then washed with PBS, 3x for 5 
min, and successively incubated biotinylated anti-rabbit/
rat immunoglobulins, 1:400 in blocking buffer at room 
temperature, for minutes, washed with PBS 3x for 5 min 
each, and incubated with ABC complex (Vector Lab, 
CA, USA), 30 min at room temperature. The slides were 
extensively washed with PBS; the reaction was developed 
with 3, 3′-Diaminobenzidine under microscopic control 
and stopped with distilled water. The slides were the 
counterstained with hematoxylin and washed 15 min in 
running tap water to bluish, dehydrated in graded alcohols 
(70°, 95°, 100°), cleared in SafeClear II and mounted in 
Permount mounting media (ThermoFisher Scientific). The 
histological slides were processed and developed at the 
same time to minimize inter-assay variability. All stained 
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slides were scanned at 40x using an Aperio CS Scanscope 
(Aperio, CA, USA) and quantified using the available 
Aperio algorithms.
CDKN2A promoter methylation analysis
The methylation status of CDKN2A was determined 
on bisulfite-treated genomic DNA by a methylation 
specific PCR method described previously [73].
HPV detection
The detection of HPV sequences was performed using 
the LCR-E7 PCR method described by Sasagawa et al. 
[74] based on four pairs of degenerated oligos designed to 
amplify E6 and the N-terminal part of E7 of most mucosal 
human papillomaviruses. Amplicons resulting from positive 
reactions were purified, Sanger-sequenced and analyzed by 
BLAST search to determine the identities.
Quantitative PCR
RNA was extracted from exponentially growing 
cultures by the TriZol method following manufacturer’s 
recommendations (Invitrogen). One microgram total 
RNA was converted to cDNA using the Superscript III kit 
(Invitrogen). Quantitative PCR reactions for SMAD7 were 
run using the PrimeTime SMAD7 Hs.PT.58.39918935 
qPCR assay from Integrated DNA Technologies 
(Coralville, IA). GAPDH was used for normalization, 
GAPDHfwd-5′-GAAGGTCGGAGTCAACGGATT, 
GAPDHrev-5′-CGCTCCTGGAAGATGGTGAT.
Western blotting
Exponentially growing cells were washed in cold 
PBS, lysed on ice in RIPA buffer (0.5% NaDOC, 0.1% 
SDS, 25 mM Hepes pH 7.5, 100 mM NaCl, 1.5 mM 
MgCl2, 0.2 mM EDTA, 1% Triton X-100, 20 mM 
β-glycerophosphate, 0.5 mM DTT, and 2% Halt Protease 
and Phosphatase Inhibitor Single-Use Cocktail [Thermo 
Scientific, Rockford, IL, USA]), and cell extracts 
collected, sonicated, and centrifuged to remove the cellular 
debris. Supernatants containing the solubilized proteins 
were quantified using the detergent compatible DC protein 
estimation kit (Bio-Rad, Hercules, CA); equal amounts 
by mass were separated by SDS-PAGE, and transferred 
to PVDF membranes (Millipore Corporation, Billerica 
MA). Equivalent loading was confirmed with Ponceau-S 
staining. For immunodetection, membranes were blocked 
for 1 h at room temperature in 5% non-fat dry milk in 
T-TBS buffer (50 mM Tris/HCl, pH 7.5, 0.15 M NaCl, 
0.1% [v/v] Tween-20), followed by 2h incubation with 
the appropriate antibodies, in 1% BSA-T-TBS buffer. 
Detection was conducted by incubating the membranes 
with horseradish peroxidase–conjugated goat anti-rabbit 
IgG secondary antibody (Southern Biotech, Birmingham, 
AL, USA) at a dilution of 1:50,000 in 5% milk-T-TBS 
buffer, at room temperature for 1 h, and visualized with 
Immobilon Western Chemiluminescent HRP Substrate 
(Millipore).
Proliferation assays
For proliferation assays, cells plated in 24 well 
plates were incubated with 0.5µCi [3H]-thymidine/ml 
(PerkinElmer, Boston, MA) for the last 4h of the treatment. 
Cells were washed twice with PBS, and then 3 times with 
cold 10% trichloroacetic acid for 10 minutes at 4°C. Cells 
were lysed in 0.5 ml 0.3N NaOH for 1h at 4°C. Samples 
(250µl) were mixed with 5 ml of scintillation fluid and 
counted.
Exome sequencing and RNAseq
Genomic DNA was isolated using the DNAeasy 
total DNA isolation kit from Qiagen (Valencia, CA). 
DNA was submitted for sequencing to the NIH Intramural 
Sequencing Center where it was further processed. Briefly, 
whole genome libraries with ~280 base inserts and paired-
end index adapters were prepared according to Illumina’s 
TruSeq DNA Sample Preparation v2 method. Batches of 
24 uniquely barcoded libraries were pooled using equal 
volumes of input and run on a MiSeq with version 2 
chemistry at a loading concentration of 6 pM. The run 
consisted of 25 cycles followed by an index read. The 
demultiplexed read counts were used to normalize the 
DNA input for exome capture where 6 libraries were 
pooled together. The exome capture was preformed 
according to Illumina’s TruSeq Exome Enrichment Kit 
protocol. Each captured exome pool was sequenced in 
2 lanes on a HiSeq2000 using version 3 chemistry. At 
least 40 million paired-end 100 base reads were obtained 
for each sample. Data was processed using RTA version 
1.17.20 and CASAVA 1.8.2. For RNAseq samples Poly-A 
selected mRNA libraries were constructed from 1 µg 
total RNA using the Illumina TruSeq RNA Sample Prep 
V2 Kits according to manufacturer’s instructions except 
where noted. The cDNAs were fragmented to ~275 bp 
using a Covaris E210. Amplification was performed 
using 8 cycles to minimize the risk of over-amplification. 
Unique barcode adapters were applied to each library. 
Libraries were pooled in groups of 7–12 for sequencing. 
The pooled libraries were sequenced on multiple lanes 
of a HiSeq2000 using version 3 chemistry to achieve a 
minimum of 40 million 100 base read pairs. The data was 
processed using RTA version 1.12.4.2 and CASAVA 1.8.2.
Data analysis and sample filtering
For DNAseq studies, reads were mapped to the 
human reference genome (hg19) by the Novoalign 
aligner. Mapped reads were further processed using the 
GATK pipeline [75] involving realignment around indels, 
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removal of duplicated reads, base scores recalibration and 
mutation calling. Multisample VCF files were annotated 
using the ANNOVAR software [76]. Due to the absence 
of matching normal DNA for each cell line, we defined a 
filtering strategy based upon modifications on two recently 
described approaches to approximate somatic mutations 
on the NCI-60 cell line panel [77] and the COSMIC Cell 
Line Project [14], in which somatic mutation calling was 
approximated by additional filtering rejecting all the non-
reference alleles present in the ESP6500 database in order 
to exclude alleles present in the normal population, except if 
the allele was present in the COSMIC v64 database [16]. In 
addition, all the non-reference alleles left after the previous 
filtering step were discarded if were present in more than 
3 cell lines as likely represented putative SNPs not captured 
in the ESP6500 project, again preserving those alleles 
present in COSMIC v64. The Strand NGS software (Strand 
Life Sciences, Bangalore, India) was used to compute 
copy number variations (CNV) and as a second mutation 
calling method used to confirm select mutations. For CNV 
determination, a pseudonormal sample was computed from 
the average read depths of all the OPC-22 lines and was 
used to define the copy number baseline against which 
all the OPC-22 cell lines were compared. Variant effect 
analysis was performed using the PROVEAN tool [78].
Transcriptome analysis
For RNA-Seq, the short sequenced reads were 
mapped to the human reference genome (hg19) by splice 
junction aligner GSNAP (Genomic Short-read Nucleotide 
Alignment Program) [79]. We employed several 
R/Bioconductor packages to accurately calculate the gene 
expression abundance at whole-genome level using the 
aligned records (BAM files) and to identify differentially 
expressed genes (DEGs) between different head and neck 
cancer cell lines. Briefly, the number of reads mapped 
to each gene based on the UCSC.hg19.KnownGene 
database was counted, reported and annotated using the 
GenomicFeatures, Rsamtools and org.Hs.eg.db packages. 
To identify differentially expressed genes between H&N 
cell lines groups (e.g.: normal vs. cancer cell lines), we 
utilized the edgeR-test based on the normalized number 
of reads mapped to each gene [80].
Heatmap visualization of differentially expressed 
transcripts was done with the MultiExperiment Viewer 
software (v4.9) [81]. For automated functional annotation 
and gene enrichment analysis, we used the Enrichr online 
resource [82] and the ClueGO tool [83].
Statistical Analysis
ANOVA followed by the Tukey t test was used to 
analyze the differences between experimental groups. Data 
analysis was done with GraphPad Prism version 6.0 for 
Windows (GraphPad Software, San Diego CA); P values 
of less than 0.05 were considered statistically significant.
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